Innate Pharma

Bristol-Myers Squibb | November 23, 2017

French biotech Innate Pharma says it can’t see a development path forward for its lead cancer drug lirilumab after another clinical trial miss. The Bristol-Myers Squibb-partnered checkpoint inhibitor, licensed in a $465m deal in 2011....

Pharma Tech

Innate Pharma | September 06, 2022

Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. About Lacutamab Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma an orphan disease, and peripheral T cell lymphoma. Rare cutaneous lymphomas of T lymphocytes has a poor prognos...

Pharmaphorum Media Limited | October 24, 2018

France’s Innate Pharma has gained rights to AstraZeneca’s recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago. The companies announced a deal in April 2015, which included combining Innate’s IPH2201, an antibody designed to stimulate natural killer cells to attack cancer, with AZ’s checkpoint inhibitor Imfinzi (durvalumab). Under the new agreement, AZ will take a 9.8% equity stake in the French biotech as ...

PHARMACY MARKET, PHARMA TECH

Sanofi and Innate Pharma | December 19, 2022

Innate Pharma SA and Sanofi announced an expansion of their collaboration, with Sanofi licensing a natural killer cell engager program targeting B7H3 from Innate’s ANKETTM. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Innate and Sanofi signed a first NK cell engagers collaboration in 2016 for the generation and evaluation of up to tw...